Philogen SpA
PHIL
Company Profile
Business description
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Contact
Piazza La Lizza No. 7
Siena53100
ITAT: +39 0577206941
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
174
Stocks News & Analysis
stocks
The shunned ASX player offering attractive value
Making the case for coal amidst a tough few years for investors
stocks
What did Morningstar subscribers buy and sell during November?
And what do our analysts think of the investments?
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,728.50 | 26.20 | -0.30% |
| CAC 40 | 7,303.28 | 47.86 | 0.66% |
| DAX 40 | 20,232.14 | 215.39 | 1.08% |
| Dow JONES (US) | 45,014.44 | 308.91 | 0.69% |
| FTSE 100 | 8,335.81 | 23.60 | -0.28% |
| HKSE | 19,742.46 | 3.86 | -0.02% |
| NASDAQ | 19,735.12 | 254.21 | 1.30% |
| Nikkei 225 | 39,276.39 | 27.53 | 0.07% |
| NZX 50 Index | 12,896.67 | 196.51 | -1.50% |
| S&P 500 | 6,086.47 | 36.59 | 0.60% |
| S&P/ASX 200 | 8,462.60 | 32.60 | -0.38% |
| SSE Composite Index | 3,364.65 | 14.16 | -0.42% |